CD8A and neoplasm: Ex vivo analysis of OVCAR3 tumours at endpoint (up to 139 days post T‐cell injection) showed significantly higher frequencies of human CD3+ and CD8+ T cells, in mice administered with nfP2X7 CAR‐T cells than in those administered with UT cells (Figure 5a and c).